Clinical review report: Ticagrelor (Brilinta) indication : co‐administered with low‐dose acetylsalicylic acid (ASA: 75‐150 mg), is indicated for the secondary prevention of atherothrombotic events in patients with a history of myocardial infarction (MI occurred at least one year ago) and a high risk of developing an atherothrombotic event
The objective was to perform a systematic review of the beneficial and harmful effects of ticagrelor 60 mg and 90 mg tablets co-administered with low-dose (75 mg to 150 mg) acetylsalicylic acid, for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction t...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
CADTH
2016, August 2016
|
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective was to perform a systematic review of the beneficial and harmful effects of ticagrelor 60 mg and 90 mg tablets co-administered with low-dose (75 mg to 150 mg) acetylsalicylic acid, for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction that occurred at least one year ago, and a high risk of developing an atherothrombotic event |
|---|---|
| Physical Description: | 1 PDF file (viii, 52 pages) illustrations |